- Home
- DMLP vs ORIC Comparison
DMLP vs ORIC Comparison
Compare DMLP & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMLP
- ORIC
- Stock Information
- Founded
- DMLP 2003
- ORIC 2014
- Country
- DMLP United States
- ORIC United States
- Employees
- DMLP N/A
- ORIC N/A
- Industry
- DMLP Oil & Gas Production
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- DMLP Energy
- ORIC Health Care
- Exchange
- DMLP Nasdaq
- ORIC Nasdaq
- Market Cap
- DMLP 1.1B
- ORIC 1.1B
- IPO Year
- DMLP N/A
- ORIC 2020
- Fundamental
- Price
- DMLP $22.88
- ORIC $12.86
- Analyst Decision
- DMLP
- ORIC Strong Buy
- Analyst Count
- DMLP 0
- ORIC 8
- Target Price
- DMLP N/A
- ORIC $16.57
- AVG Volume (30 Days)
- DMLP 145.5K
- ORIC 1.1M
- Earning Date
- DMLP 11-06-2025
- ORIC 11-06-2025
- Dividend Yield
- DMLP 14.06%
- ORIC N/A
- EPS Growth
- DMLP N/A
- ORIC N/A
- EPS
- DMLP 1.13
- ORIC N/A
- Revenue
- DMLP $143,803,000.00
- ORIC N/A
- Revenue This Year
- DMLP N/A
- ORIC N/A
- Revenue Next Year
- DMLP N/A
- ORIC N/A
- P/E Ratio
- DMLP $20.16
- ORIC N/A
- Revenue Growth
- DMLP N/A
- ORIC N/A
- 52 Week Low
- DMLP $22.56
- ORIC $3.90
- 52 Week High
- DMLP $34.88
- ORIC $14.93
- Technical
- Relative Strength Index (RSI)
- DMLP 34.80
- ORIC 52.88
- Support Level
- DMLP $22.55
- ORIC $11.77
- Resistance Level
- DMLP $23.87
- ORIC $12.91
- Average True Range (ATR)
- DMLP 0.60
- ORIC 0.74
- MACD
- DMLP -0.18
- ORIC -0.11
- Stochastic Oscillator
- DMLP 13.19
- ORIC 53.69
About DMLP Dorchester Minerals L.P. Common Units Representing Limited Partnership Interests
Dorchester Minerals LP operates as the owner of producing and non-producing crude oil and natural gas mineral, royalty, overriding royalty, net profits and leasehold interests. The company generates revenues from royalties, net profits interests, lease bonus, and others. It has leasehold interests in approximately 592 counties and parishes in around 28 states.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.